04/18/2025
As the pharmaceutical industry evolves, the exploration of alternative and plant-derived therapies has moved from the fringe to the forefront of innovation. Cannabinoids and psilocybin—once primarily associated with natural wellness communities—are now the focus of serious research and emerging regulatory pathways aimed at treating a wide range of conditions, including chronic pain, epilepsy, anxiety, depression, and PTSD. At Mikart, we recognize the potential of these therapies and are well-positioned to support companies seeking to bring them to market....
As the pharmaceutical industry evolves, the exploration of alternative and plant-derived therapies has moved from the fringe to the forefront...